Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of Elevated Serum Branched-chain Amino Acid Levels With Longitudinal Skeletal Muscle Loss.
Imai D, Nakanishi N, Shinagawa N, Yamamoto S, Ichikawa T, Sumi M, Matsui T, Hosomi Y, Hasegawa Y, Munekawa C, Miyoshi T, Okamura T, Kitagawa N, Hashimoto Y, Okada H, Sakui N, Sasano R, Hamaguchi M, Fukui M. Imai D, et al. Among authors: hosomi y. J Endocr Soc. 2024 Jan 11;8(2):bvad178. doi: 10.1210/jendso/bvad178. eCollection 2024 Jan 5. J Endocr Soc. 2024. PMID: 38213909 Free PMC article.
Predictive power of isolated high home systolic blood pressure for cardiovascular outcomes in individuals with type 2 diabetes mellitus: KAMOGAWA-HBP study.
Hosomi Y, Ushigome E, Kitagawa N, Kitagawa N, Tanaka T, Hasegawa G, Ohnishi M, Tsunoda S, Ushigome H, Nakamura N, Asano M, Hamaguchi M, Yamazaki M, Fukui M. Hosomi Y, et al. Diab Vasc Dis Res. 2023 Nov-Dec;20(6):14791641231221264. doi: 10.1177/14791641231221264. Diab Vasc Dis Res. 2023. PMID: 38063417 Free PMC article.
Corrigendum to 'Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC' [JTO Clinical and Research Reports, Volume 5 Issue 4 (2024) 100659].
Hirata T, Uehara Y, Hakozaki T, Kobayashi T, Terashima Y, Watanabe K, Yomota M, Hosomi Y. Hirata T, et al. Among authors: hosomi y. JTO Clin Res Rep. 2024 Nov 8;6(1):100761. doi: 10.1016/j.jtocrr.2024.100761. eCollection 2025 Jan. JTO Clin Res Rep. 2024. PMID: 39758600 Free PMC article.
Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer.
Hirata T, Watanabe K, Hosomi Y, Yoh K, Usui K, Kishi K, Naka G, Tamano S, Uemura K, Kunitoh H. Hirata T, et al. Among authors: hosomi y. Jpn J Clin Oncol. 2024 Dec 20:hyae176. doi: 10.1093/jjco/hyae176. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39703183
Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study.
Sonehara K, Tateishi K, Yoh K, Usui K, Hosomi Y, Kishi K, Naka G, Watanabe K, Tamano S, Uemura K, Kunitoh H. Sonehara K, et al. Among authors: hosomi y. Thorac Cancer. 2025 Jan;16(2):e15507. doi: 10.1111/1759-7714.15507. Epub 2024 Dec 7. Thorac Cancer. 2025. PMID: 39644181 Free PMC article.
Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
Karayama M, Suda T, Yoh K, Usui K, Hosomi Y, Kishi K, Naka G, Watanabe K, Tamano S, Uemura K, Kunitoh H. Karayama M, et al. Among authors: hosomi y. Lung Cancer. 2024 Dec;198:108037. doi: 10.1016/j.lungcan.2024.108037. Epub 2024 Nov 26. Lung Cancer. 2024. PMID: 39602849
202 results